NCT00279214View on ClinicalTrials.gov

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

November 30, 2007

Conditions
SepsisSeptic Shock
Interventions
DRUG

drotrecogin alfa (activated)

Trial Locations (2)

44307

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akron

08103

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camden

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00279214 - Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock | Biotech Hunter | Biotech Hunter